Literature DB >> 1525302

The cytotoxicity of helenalin, its mono and difunctional esters, and related sesquiterpene lactones in murine and human tumor cells.

A A Grippo1, I H Hall, H Kiyokawa, O Muraoka, Y C Shen, K H Lee.   

Abstract

Naturally occurring sesquiterpene lactones and their semisynthetic derivatives, such as the O = C-C = CH-bearing helenalin and its esters, have been shown to demonstrate potent cytotoxicity against the growth of murine L1210 lymphoid leukemia and human Tmolt3 leukemia, colon adenocarcinoma, HeLaS3, lung bronchogenic, KB, osteosarcoma, and glioma cells. The modes of action of helenalin in L1210 cells are the inhibition of DNA, RNA, and protein syntheses. This study confirms that thiol bearing enzymes of nucleic acid metabolism were significantly inhibited, e.g. DNA polymerase alpha, IMP hydrogenase, and ribonucleoside reductase. The addition of GSH to the reaction medium demonstrated total recovery of L1210 ribonucleoside reductase activity. Helenalin reduced cellular GSH levels in L1210 cells. Helenalin also reduced all four pool levels of d(NTP)s which would account for part of the observed inhibition of DNA synthesis. Reductions in the ribonucleotide pool levels were also generally evident after drug treatment. Thus, the sesquiterpene lactones appear to have more than one mode of action in L1210 cells. All of the modes of actions of helenalin are feasible mechanisms to lower nucleic acid synthesis and cause cell death of the L1210 leukemia cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1525302

Source DB:  PubMed          Journal:  Drug Des Discov        ISSN: 1026-7921


  5 in total

1.  Targeting NF-κB p65 with a Helenalin Inspired Bis-electrophile.

Authors:  John C Widen; Aaron M Kempema; Peter W Villalta; Daniel A Harki
Journal:  ACS Chem Biol       Date:  2016-11-28       Impact factor: 5.100

2.  Increased intracellular Ca2+ signaling caused by the antitumor agent helenalin and its analogues.

Authors:  G Powis; A Gallegos; R T Abraham; C L Ashendel; L H Zalkow; G B Grindey; R Bonjouklian
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

3.  V. Amygdalina: Folk Medicine, Analysis, and Potential Application for Cancer Treatment.

Authors:  Ernest B Izevbigie; C B Howard; K S Lee
Journal:  Curr Pharm Anal       Date:  2008       Impact factor: 0.890

4.  Helenalin-mediated post-transcriptional regulation of p21(Cip1) inhibits 3T3-L1 preadipocyte proliferation.

Authors:  Karishma M Fernandes; Corinth A Auld; Robin G Hopkins; Ron F Morrison
Journal:  J Cell Biochem       Date:  2008-10-15       Impact factor: 4.429

5.  Mechanism of Action of the Sesquiterpene Compound Helenalin in Rhabdomyosarcoma Cells.

Authors:  Hakmin Mun; Helen Elizabeth Townley
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.